Related Experiment Videos
Novel approaches for the prevention of restenosis
L Gruberg1, R Waksman, L F Satler
1Cardiac Catheterization Laboratory, Washington Hospital Center, Washington, DC, USA. lxg6@mhg.edu
Insights
Restenosis, the re-narrowing of coronary arteries after procedures, is a major limitation. Intracoronary radiation shows promise as a non-pharmacological approach to control tissue proliferation and prevent restenosis.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
- Biomedical Engineering
Background:
- Restenosis, or re-narrowing of coronary arteries post-angioplasty or stenting, limits the success of percutaneous coronary revascularization.
- While balloon angioplasty-induced restenosis involves elastic recoil, smooth muscle proliferation, and remodeling, stent-induced restenosis primarily results from smooth muscle hyperplasia and matrix proliferation.
- Most pharmacological agents have proven ineffective in preventing restenosis in clinical trials, despite success in animal models.
Purpose of the Study:
- To review clinical trials focusing on promising treatments for coronary artery restenosis.
- To highlight interventions that warrant further investigation for controlling excessive tissue proliferation.
- To assess the efficacy of non-pharmacological approaches in managing restenosis.
Main Methods:
- Review of clinical trials evaluating pharmacological and non-pharmacological interventions for restenosis.
- Focus on intracoronary radiation (gamma- and beta-emitting sources) and novel drug delivery systems.
- Analysis of studies investigating antiproliferative agents, recombinant DNA, and growth factor regulators.
Main Results:
- Intracoronary radiation has demonstrated encouraging results in controlling excessive tissue proliferation in a significant number of patients.
- Novel antiproliferative agents and local drug delivery systems show promising outcomes.
- Few pharmacological agents have translated success from animal models to clinical trials for preventing neointimal hyperplasia.
Conclusions:
- Intracoronary radiation represents a potent non-pharmacological strategy for managing restenosis.
- Combining stents with pharmacological or non-pharmacological inhibition of neointimal hyperplasia may further reduce restenosis incidence.
- Controlling the restenotic process is crucial for the continued viability of percutaneous coronary revascularization.
Abstract:
Restenosis, the re-narrowing of the lumen of the coronary artery, in the months following a successful percutaneous balloon angioplasty or stenting, remains the main limitation to percutaneous coronary revascularisation. Serial intravascular ultrasound studies have shown that restenosis after conventional balloon angioplasty represents a complex interplay between elastic recoil, smooth muscle proliferation and vascular remodelling, while restenosis after stent deployment is due almost entirely to smooth muscle hyperplasia and matrix proliferation. Despite intensive investigation in animal models and in clinical trials, most pharmacological agents have been found to be ineffective in preventing restenosis after percutaneous balloon angioplasty or stenting. Although studies frequently report success in the suppression of neointimal proliferation in animal models of balloon vascular injury, few of them have been successful in clinical trials. Lately, the advent of endovascular radiation, new antiproliferative agents, recombinant DNA, growth factor regulators and novel local drug delivery systems have shown promising results. In the past five years, intracoronary radiation with gamma- and beta-emitting sources has been evaluated intensively with very encouraging results. This is the first potent non-pharmacological approach that has been successful in a large number of patients in controlling excessive tissue proliferation. It is very likely that a combination of stents and pharmacological and/or non-pharmacological inhibition of neointimal hyperplasia will likely result in further reductions in the incidence if restenosis. The continued attractiveness of percutaneous coronary revascularisation, as an alternative to medical treatment or bypass surgery for patients with coronary artery disease, will depend upon our ability to control the restenotic process. Due to the vast literature on the subject, this review will focus mainly on clinical trials that show the most promise and will highlight those that warrant further investigation.